Dae Gon Ha's Stock Ratings

Stifel Analyst

Dae Gon Ha is an analyst at Stifel. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 10/15/2024

Overall Average Return

5.13%

Smart Score

53.2%

Overall Average Return Percentile

47th

Number of Ratings

68
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
Analyst Ratings For Mirum Pharmaceuticals
Analyst Ratings For Mirum Pharmaceuticals
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market trading.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free